AB-1005 is under clinical development by Asklepios BioPharmaceutical and currently in Phase I for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, Phase I drugs for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AB-1005 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of Parkinson's disease and multiple system atrophy. The drug candidate comprises of an adeno-associated virus serotype 2 (AAV2) vector carrying the glial cell derived neurotrophic factor (GDNF) gene. It is administered by parenteral route. It is developed based on Adeno-associated virus vector (AAV) technology.
Asklepios BioPharmaceutical overview
Asklepios BioPharmaceutical (AskBio) is AAV gene therapy development company that develops and markets novel protein and cellular based therapies. Its product pipeline includes therapies for the treatment of neuromuscular, central nervous system, heart related diseases including pompe, limb-girdle 2i, huntington’s, epilepsy, parkinson’s, and congestive heart failure (nanocor). AskBio has developed library of AAV biological nano particles that provides unsurpassed transduction. It serves pharmaceutical and biotechnology companies. AskBio is headquartered in Durham, North Carolina, the US.
For a complete picture of AB-1005’s drug-specific PTSR and LoA scores, buy the report here.